Product Details:
Payment & Shipping Terms:
|
| Product Name: | Mefloquine Tablets | Composition: | Each Tablet Contains:Mefloquine 250MG |
|---|---|---|---|
| Standard: | BP/USP/CP | Package: | 1*8TABLETS/BOX*200/CATON |
| Indications: | Prophylaxis Of Plasmodium Falciparum Malaria | Storage Instructions: | Store Below 25°C.Protect From Moisture. |
| Expiration Date: | 3 Years | ||
| High Light: | anti malarial drug,antimalarial medications |
||
Mefloquine Tablets 250MG Anti malaria Medicine 1*8's / Box
Mefloquine Tablets Anti malarial 250MG
COMPOSITION:
Each tablet contains mefloquine hydrochloride 274 mg equivalent to mefloquine 250 mg.
PHARMACOLOGICAL ACTION:
Mefloquine is a quinoline methanol derivative, structurally related to quinine. Mefloquine is a blood schizontozide with effects on the asexual blood forms of the malarial pathogens that affect humans (Plasmodium falciparum, P. vivax). It is also active against the gametocytes of P. vivax. Its mechanism of action is unknown. Mefloquine has no effect on the hepatic stage of malaria parasites. Strains of P. falciparum resistant to mefloquine have been reported.
Cross-resistance between halofantrine and mefloquine has been observed. Resistance to mefloquine as well as to any other antimalarial may occur in any endemic area. Mefloquine resistance has been described. Resistance patterns occur and vary from region to region and with time.
INDICATIONS:
MEFLIAM tablets are indicated for prophylaxis of Plasmodium falciparum malaria, in regions where P. falciparum strains resistant to 4-aminoquinolines (e.g. chloroquine) occur. MEFLIAM may be effective against malaria parasites resistant to proguanil, pyrimethamine-sulfonamide combinations.
CONTRA-INDICATIONS:
MEFLIAM is contra-indicated in the following:
| • | Patients with known hypersensitivity to mefloquine or related compounds (e.g. quinine and quinidine). |
| • | Patients with depression or a past history of depression, generalized anxiety disorder, psychosis, including schizophrenia or other psychiatric disturbances. |
| • | Patients with a history of convulsions. |
| • | Children of body weight less than 5 kg. |
| • | Patients with impaired renal or hepatic function. |
| • | The safety in pregnancy and lactation has not been established. |
DOSAGE AND DIRECTIONS FOR USE:
The following weekly doses of MEFLIAM are recommended:
| Body weight: | Weekly dose for prophylaxis: | |
| Up to 19 kg | 1/4 tablet (62,5 mg) | |
| 20-30 kg | ½ tablet (125 mg) | |
| 31-45 kg | 3/4 tablet (187,5 mg) | |
| >45 kg | 1 tablet (250 mg) |
Experience with MEFLIAM in infants less than 3 months old or weighing less than 5 kg does not exist.
The first dose should betaken one week before arrival in an endemic area and subsequent weekly doses should be taken on the same day of each week. Prophylaxis should be continued for four weeks after leaving the malarial area, and should not exceed 3 months' duration. The tablets should be taken after food with plenty of fluids.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Dizziness or disturbed sense of balance, nausea, vomiting, loose stools or diarrhoea, abdominal pain and loss
of appetite. Less frequent reactions reported include headache, somnolence and sleep disorders (insomnia, abnormal dreams), myalgia, feeling of weakness, visual disturbances, palpitations, bradycardia, irregular pulse and extrasystoles, AV-block, hair loss, rash or pruritus, urticaria, convulsions, psychological changes, transient elevation of transaminases, leucopoenia or leucocytosis and decrease of platelets. Erythema multiforme and Stevens-Johnson syndrome have been reported. Transient cardiac conduction alterations and paraesthesia have been observed in patients taking mefloquine. These adverse events can be observed several weeks after the last dose has been taken.
Psychiatric reactions, sometimes disabling and prolonged, have been reported in association with mefloquine.
STORAGE INSTRUCTIONS:
Store below 25°C. Keep out of reach of children.
Protect from moisture.
